Clinical trial
ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
NCT06998407
Study timeline
Study start (actual)2025-08-20Date precision: day
Registry last updated2026-08-10
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HR+/HER2- Breast Cancerunresolved
HR+, HER2-, Advanced Breast Cancerunresolved
Interventions
AVZO-021DRUG
FulvestrantDRUG · verified · RxNorm: fulvestrant
LetrozoleDRUG · verified · RxNorm: letrozole
AVZO-023DRUG
Sponsors & collaborators
Avenzo Therapeutics, Inc.lead sponsor
Mapped research locations
Los AngelesCalifornia, United States2New YorkNew York, United States1HoustonTexas, United States1BostonMassachusetts, United States1San AntonioTexas, United States1NashvilleTennessee, United States1SeattleWashington, United States1ClevelandOhio, United States1ColumbusOhio, United States1TampaFlorida, United States1OrlandoFlorida, United States1New HavenConnecticut, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06998407 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.